187 related articles for article (PubMed ID: 15149157)
1. BCL-2 and P53 expression in endometrial carcinoma.
Erkanli S; Eren F; Pekin S; Bagis T
J Exp Clin Cancer Res; 2004 Mar; 23(1):97-103. PubMed ID: 15149157
[TBL] [Abstract][Full Text] [Related]
2. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
4. BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry.
Porichi O; Nikolaidou ME; Apostolaki A; Tserkezoglou A; Arnogiannaki N; Kassanos D; Margaritis L; Panotopoulou E
Anticancer Res; 2009 Oct; 29(10):3977-82. PubMed ID: 19846939
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 and p53 expression in stage I endometrial carcinoma.
Giatromanolaki A; Sivridis E; Koukourakis MI; Harris AL; Gatter KC
Anticancer Res; 1998; 18(5B):3689-93. PubMed ID: 9854478
[TBL] [Abstract][Full Text] [Related]
7. [Bcl-2 gene expression in endometrial carcinoma].
Sheng X; Song H; He X
Zhonghua Zhong Liu Za Zhi; 1998 Sep; 20(5):365-6. PubMed ID: 10921033
[TBL] [Abstract][Full Text] [Related]
8. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
9. Expression of the apoptosis-related genes Bcl-2 and p53 in clinical samples from endometrial carcinoma patients.
González-Rodilla I; Verna V; Muñoz AB; Estévez J; Boix M; Schneider J
Anticancer Res; 2011 Dec; 31(12):4191-3. PubMed ID: 22199279
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
[TBL] [Abstract][Full Text] [Related]
11. bcl-2 expression in endometrial hyperplasia and carcinoma.
Niemann TH; Trgovac TL; McGaughy VR; Vaccarello L
Gynecol Oncol; 1996 Dec; 63(3):318-22. PubMed ID: 8946865
[TBL] [Abstract][Full Text] [Related]
12. bcl-2 expression and the development of endometrial carcinoma.
Chhieng DC; Ross JS; Ambros RA
Mod Pathol; 1996 Apr; 9(4):402-6. PubMed ID: 8729980
[TBL] [Abstract][Full Text] [Related]
13. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
14. bcl-2 and p53 in endometrial adenocarcinoma.
Taskin M; Lallas TA; Barber HR; Shevchuk MM
Mod Pathol; 1997 Jul; 10(7):728-34. PubMed ID: 9237185
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis, bcl-2 expression, and proliferation in benign and malignant endometrial epithelium: An approach using multiparameter flow cytometry.
Morsi HM; Leers MP; Radespiel-Tröger M; Björklund V; Kabarity HE; Nap M; Jäger W
Gynecol Oncol; 2000 Apr; 77(1):11-7. PubMed ID: 10739685
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
17. The association between p53 expression, stage and histological features in endometrial cancer.
Ragni N; Ferrero S; Prefumo F; Muschiato B; Gorlero F; Gualco M; Fulcheri E
Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):111-6. PubMed ID: 15894417
[TBL] [Abstract][Full Text] [Related]
18. [Expression of oncogene proteins Bag-1, p53, and bcl-2 in endometrium adenocarcinoma with different rate of differentiation].
Khadzhiolov N; Ivanov S
Akush Ginekol (Sofiia); 2004; 43 Suppl 2():35-6. PubMed ID: 15518275
[No Abstract] [Full Text] [Related]
19. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables.
Erdem O; Erdem M; Dursun A; Akyol G; Erdem A
Int J Gynecol Pathol; 2003 Jul; 22(3):254-60. PubMed ID: 12819392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]